Medical Technologies

KEI statement on adoption of Eshoo/Barton amendment

In a roll call vote, the Eshoo/Barton amendment passed by a vote of 47 to 11. A number of consumer groups are issuing statements. This is the KEI statement on the vote.

James Love, Director Knowledge Ecology International (KEI),
(+1) (202) 361-3040, james.love@keionline.org

Howard Dean: “I’m actually not a shill for the bio industry”

The Center for American Progress hosted a video conference of Dr. Howard Dean talking about Health Care reform on Tueday. The video is on the web here. On this one hour program, Howard Dean spends a little over 3 minutes responding to allegations that he is a “shill” for BIO, on the issue of biosimilars.

Howard Dean as a shill for BIO, on Biosimilars bill

The July 20, 2009 issue of BioCentury has an extensive report on the “Biosimilar fire Drill.” It discusses in detail the lobbying by the Biotechnology Industry Association (BIO, bio.org) to defeat efforts by President Obama, OMB, the FTC, Representative Waxman, Senator Brown, AARP, Public Citizen, PIRG, Consumers Union, KEI, Essential Action, and others, to reform the regulation to biologic medicines, so there is more generic competition.

Margaret Chan on “new initiatives, and new incentive schemes”

At the WIPO Conference on Intellectual Property and Public Policy Issues today, Margaret Chan, the Director General of the World Health Organization, made the following speech at WIPO’s Conference on Intellectual Property and Public Policy Issues on the topic of “Strengthening Multilateral Cooperation on IP and Public Health” where she shared the limelight with Pascal Lamy, Director General of the World Trade Organ

WHO releases document detailing stakeholder implementation of Global Strategy: Public health, innovation and IP

On Monday, 18 May 2009, WHO released document A62/16 Add.3 entitled “Open paragraphs on stakeholders“.

The link for this document is: http://apps.who.int/gb/ebwha/pdf_files/A62/A62_16Add3-en.pdf

The cover sheet of this document states:

Submissions of Member States and Stakeholders to WHO Expert Working Group on R&D Financing

The contributions from WHO Member States and other Stakeholders to the Expert Working Group on R&D financing are now available on the WHO website.

The following extract is taken from the WHO public hearing website:

Public Health Consumer Groups respond to 2009 USTR Special 301 Report

Public Health and Consumer Groups respond to 2009 USTR Special 301 Report

Essential Action, AU Program on Information Justice and IP, Knowledge Ecology International, Forum on Democracy and Trade, Health GAP and Oxfam America

FOR IMMEDIATE RELEASE | April 30, 2009
Contact Info for each organization below with each quotation

Statement by Brazil at TRIPS Council: Public Health dimension of TRIPS Agreement

On 3 March 2009, the following intervention was delivered by Ambassador Roberto Azevêdo, Permanent Representative of Brazil to the WTO and other economic organizations in Geneva.

_____________________________________________________________________________________________

TRIPS Council
Agenda item ‘M’ – OTHER BUSINESS – Public Health dimension of TRIPS Agreement

Statement by Brazil

Mr. Chairman,

FDA Priority Review Voucher, KEI comments

KEI filed comments on Friday on the FDA request for comments on the Priority Review Voucher.

Dr. Yusuf Hamied at DNDi’s Geneva offices

James Love and Dr. Yusuf K. Hameid of CIPLA, at DNDi Geneva offices, September 2008James Love and Dr. Yusuf K. Hameid of CIPLA, at DNDi Geneva offices, September 2008

Syndicate content